ClinicalTrials.gg
CompletedNCT00090064Updated Jun 6, 2025Results posted

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

A Phase 2 interventional study of Midomafetamine HCl and Lactose placebo pill in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
20th of 38
23 · median 25
Started
2004
the only one that year
Phase 2
28 of 38
10 open now
Registered
1st of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 20th largest by enrollment, is the only one that started in 2004, is one of 28 in phase 2, and was the 1st registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD). The main question it aims to answer is: Is there a reduction in PTSD symptoms among people given MDMA-assisted therapy compared to placebo with therapy?

Participants will receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory psychotherapy sessions and non-drug integrative sessions.

The study will test whether MDMA-assisted therapy can be safely given to participants. Researchers will compare PTSD symptoms in the MDMA-assisted therapy group to the placebo with therapy group to see if there is a reduction in symptoms after the treatment period.

Read the detailed description

This randomized, double-blind placebo-controlled pilot study assessed the safety and effectiveness of MDMA-assisted therapy among people with chronic, treatment-resistant PTSD, including veterans. Participants were assigned to receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart during Stage 1 of the study. During these experimental sessions, participants received an initial dose of 125 mg of MDMA HCl followed by a supplemental dose of 62.5 mg of MDMA HCl, or they received initial and supplemental doses of inactive placebo. Psychotherapists and independent raters were blinded to participants' treatment conditions. This treatment period also consisted of non-drug preparatory therapy sessions and non-drug integration therapy sessions.

During Stage 2 of the study, the blind was broken and participants assigned to receive MDMA-assisted therapy in Stage 1 underwent a third open-label experimental session of MDMA-assisted therapy. Participants assigned placebo with therapy during Stage 1 who chose to enroll in Stage 2 underwent three open-label sessions of MDMA-assisted therapy. Outcome measures were administered two months after the second experimental session in Stage 1 and four to six weeks after the second MDMA-assisted therapy session in Stage 2. A final data-collection session took place at two months after the third experimental session.

The primary objective of the study was to measure change in PTSD symptoms via CAPS-IV across the study in participants receiving MDMA-assisted therapy versus placebo with therapy.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • MDMA
  • Methylenedioxymethamphetamine
  • PTSD
  • psychotherapy
  • midomafetamine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have current PTSD (within the past 6 months) in response to crime victimization, including childhood sexual or physical abuse, or meet criteria for PTSD in response to combat;
  • Have a CAPS score showing moderate to severe PTSD symptoms;
  • They must either:

    1. Have had at least one unsuccessful attempt at treatment for PTSD with a SSRI and psychotherapy;
    2. Be a veteran with PTSD symptoms that have endured for no less than one year but no more than five years
  • Be at least 18 years old;
  • Must be generally healthy;
  • Willing to remain overnight at the study site;
  • Agree to have transportation home the morning after experimental sessions;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children and agree to use an effective form of ;
  • Are proficient in reading English;

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or are able to bear children and are not practicing an effective means of ;
  • Weigh less than 50 kg or more than 105 kg;
  • Are unable to give adequate ;
  • Prior use of "Ecstasy" (illicit drug preparations purported to contain MDMA) more than 5 times or at any time within the previous 6 months;
  • Have a history of certain excluded medical disorders.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    MDMA-assisted therapy (125 mg)

    Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2 to 2.5 hours later by a second dose of 62.5 mg midomafetamine HCl during two 8-hour long blinded therapy sessions.

    Drug: Midomafetamine HCl · Behavioral: Therapy

  • Placebo comparator
    Placebo with therapy

    Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.

    Drug: Lactose placebo pill · Behavioral: Therapy

Interventions

  • 125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl

    Also known as: MDMA HCl, 3,4-methylenedioxymethamphetamine, MDMA, Midomafetamine

  • DrugLactose placebo pill

    125 mg followed by a supplemental half-dose of 62.5 mg

    Also known as: Placebo

  • BehavioralTherapy

    Non-directive therapy provided by a team of two co-therapists

06

What researchers measure

Primary outcomes

  1. Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to 2 months post second experimental session

Secondary outcomes

  1. Change in Impact of Events Scale Revised (IES-R) From Baseline to 2-month Follow-up

    The Impact of Events Scale Revised (IES-R) is a 22-item self-report measure (for DSM-IV) designed to measure the extent to which a given stressful life event produces subjective distress. Each item corresponds directly to 14 of the 17 DSM-IV symptoms of PTSD and is rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") for the extent to which the item was true for the participant during the past seven days. The IES-R yields a total score ranging from 0 to 88 with higher scores indicated greater distress.

    Time frame: Baseline to 2 months post second experimental session

07

Results

Posted Oct 25, 2021

Participant flow

Participants were recruited via letters to psychotherapists and internet advertisements.

Participant flow — Overall Study
MilestoneMDMA-assisted TherapyPlacebo With Therapy
Started158
Completed138
Not completed20

Outcome measures

PrimaryChange in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to 2 months post second experimental session
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up
score on a scaleMDMA-assisted TherapyPlacebo With Therapy
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up-55.2 ± 33.54-20.5 ± 20.47
SecondaryChange in Impact of Events Scale Revised (IES-R) From Baseline to 2-month Follow-up

The Impact of Events Scale Revised (IES-R) is a 22-item self-report measure (for DSM-IV) designed to measure the extent to which a given stressful life event produces subjective distress. Each item corresponds directly to 14 of the 17 DSM-IV symptoms of PTSD and is rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") for the extent to which the item was true for the participant during the past seven days. The IES-R yields a total score ranging from 0 to 88 with higher scores indicated greater distress.

Time frame:
Baseline to 2 months post second experimental session
Reported as:
Mean · score on a scale
Change in Impact of Events Scale Revised (IES-R) From Baseline to 2-month Follow-up
score on a scaleMDMA-assisted TherapyPlacebo With Therapy
Change in Impact of Events Scale Revised (IES-R) From Baseline to 2-month Follow-up-29.7 ± 21.3-12.9 ± 15.00

Adverse events

Collected over On or after first day of study intervention through to follow-up visit (approximately 7 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MDMA-assisted Therapy0/15 (0%)2/15 (13.3%)13/15 (86.7%)
Placebo With Therapy0/8 (0%)0/8 (0%)8/8 (100%)
SRRs: MDMA-assisted Therapy0/15 (0%)0/15 (0%)15/15 (100%)
SRRs: Placebo With Therapy0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventMDMA-assisted TherapyPlacebo With TherapySRRs: MDMA-assisted TherapySRRs: Placebo With Therapy
Clavicle fractureMusculoskeletal and connective tissue disorders1/150/8——
SyncopeNervous system disorders1/150/8——
Most frequent other events
Showing 10 of 86
Most frequent other events
EventMDMA-assisted TherapyPlacebo With TherapySRRs: MDMA-assisted TherapySRRs: Placebo With Therapy
AnxietyPsychiatric disorders2/154/814/148/8
FatigueGeneral disorders4/152/814/158/8
HeadacheNervous system disorders1/150/813/148/8
InsomniaPsychiatric disorders0/151/812/138/8
FatigueGeneral disorders0/150/814/158/8
Increased irritabilityGeneral disorders0/150/88/127/8
NauseaGastrointestinal disorders1/150/811/156/7
Jaw clenching, tight jawGeneral disorders0/150/812/146/8
NauseaGeneral disorders0/150/811/156/7
DizzinessNervous system disorders1/150/88/146/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)MDMA-assisted TherapyPlacebo With TherapyTotal
Mean40.5 ± 7.440.8 ± 7.040.6 ± 70.1
Sex: Female, Male
Sex: Female, Male(Participants)MDMA-assisted TherapyPlacebo With TherapyTotal
Female11718
Male415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MDMA-assisted TherapyPlacebo With TherapyTotal
Caucasian14822
Other101
08

Study locations

1 site
  • Offices of Michael Mithoefer MD
    Mount Pleasant, South Carolina 29464, United States
09

References and documents

Publications

  • Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of +/-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011 Apr;25(4):439-52. doi: 10.1177/0269881110378371. Epub 2010 Jul 19. PubMed 20643699 ↗
  • Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013 Jan;27(1):28-39. doi: 10.1177/0269881112456611. Epub 2012 Nov 20. PubMed 23172889 ↗
  • Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PubMed 32500209 ↗
  • Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. PubMed 31572236 ↗
  • Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PubMed 31065731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of May 2008 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2021, 13 years 5 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2004
First posted
Aug 25, 2004
Start
Mar 12, 2004
Primary completionActual
May 2, 2008
CompletionActual
Jun 21, 2010
Results delay requested
Jul 31, 2011
Results first posted
Oct 25, 2021
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00090064
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Aug 25, 2004
Start date
Mar 12, 2004
Primary completion
May 2, 2008
Completion
Jun 21, 2010
Results posted
Oct 25, 2021
Last update
Jun 6, 2025

Study contacts

Michael Mithoefer, MD
principal investigator · Private Practice
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion